BuMgNiPr2: A New Base for Stoichiometric, Position-Selective Deprotonation of Cyclopropane Carboxamides and Other Weak CH Acids This work was supported in part by Eastman Chemical. We are grateful to Z. Hantosi and C.-H. Lee for trial experiments, to I. Steele for the X-ray analyses, and to Professor S. Shuto of Hokkaido University for samples of Milnacipran precursors.
The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
Heteroatom‐directedCH borylation of cyclopropanes and cyclobutanes was achieved with silica‐supported monophosphane–Ir catalysts. Borylation occurred at the CH bonds located γ to the directingN or O atoms with exceptional cis stereoselectivity relative to the directinggroups. This protocol was applied to the borylation of a tertiary CH bond of a ring‐fused cyclopropane.
PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES
申请人:Mezei Tibor
公开号:US20100274020A1
公开(公告)日:2010-10-28
The invention relates to a process for the preparation of cyclopropyl benzyl ketone compounds of formula (II) wherein R
1
represents fluorine or chlorine atom or C
1-4
alkoxy group, by the reaction of a Grignard reagent, obtained from the reaction of compound of formula (V), wherein X represents chlorine or fluorine atom, with the compound of formula (IV), wherein R
2
represents C
1-4
alkyl group, having a straight or branched chain. The process can be applied preferably on industrial scale. Compound of formula (II), wherein R represents a fluorine atom in position 2 is an intermediate of the preparation process of prasugrel, which is a platelet inhibitor used in the therapy.
EnantioselectiveC(sp3)−H activation in simple amides has been achieved by using palladium(II) catalysis with a chiral sulfoxide-2-hydroxypridine (SOHP) ligand. We report herein an efficient asymmetric PdII/SOHP-catalyzed β-C(sp3)−Harylation of aliphatictertiaryamides (up to 93 % yield and 99 % ee), in which the SOHP ligand plays a key role in the stereoselective C−H deprotonation-metalation step